Company profile
oxfordendovascular
Oxford Endovascular Limited is a UK company with status active founded in 2015 based in South East England.
Updated 06 Jun 2026 16:52
Financial period: 1 Oct 2023 to 30 Sep 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
TM01 | Transaction MzQzODQyMDE5NGFkaXF6a2N4
Published 04 Oct 2024 10:51
CS01 | Transaction MzQzNTk3NTI2OGFkaXF6a2N4
Published 16 Sep 2024 08:59
CH01 | Transaction MzQzNTk3NDI4MmFkaXF6a2N4
Published 16 Sep 2024 08:53
Company registered at Companies House
The company was an Oxford University spin-off aimed to commercialise a novel flow diverter for direct treatment of cerebral aneurysms. The company has successfully raised £2 million to carry out product finalisation and clinical trials. The EPSRC funded project enabled me to start research on stents and flow diversion stent. Though my technology used by the company does not directly come from the outcome of this project, but the principles were the same. The project enabled the PI to think beyond aortic aneurysms, and later the PI carried on research on cerebral aneurysms and came up with the idea that led to the creation of the company.
Oxford Endovascular develops mesh tubes to help treat patients suffering from brain aneurysms.
The company has a novel approach which is vastly different from existing devices. Its success will greatly enhance the treatment to cerebral aneurysms that cannot be effectively dealt with by existing devices.
1 May 2025 to 31 Oct 2026
Annually 6,600 UK citizens suffer a subarachnoid haemorrhage (SAH) resulting from a ruptured intracranial aneurysm (IA), with 40% mortality and 40% morbidity (severe neurological disabilities). However, SAHs are entirely avoidable through early intervention. Over the last decades, IA standard-of-care has moved from invasive, risky, and expensive open surg...
1 Nov 2020 to 31 Jan 2022
Annually 6,600 UK citizens suffer a subarachnoid haemorrhage (SAH) resulting from the rupture of an intracranial aneurysm (IA), of whom 40% will die and 40% will suffer severe disabilities. However, SAH's are entirely avoidable through early intervention. Over the last decades clinical interventions have increasingly moved from invasive, risky, and expens...
